NasdaqGS:CRNXPharmaceuticals
Does EU Approval Of Oral Acromegaly Drug PALSONIFY Redefine The Bull Case For Crinetics (CRNX)?
Crinetics Pharmaceuticals announced that the European Commission has approved PALSONIFY (paltusotine), the first once-daily oral SST2 agonist, for treating adult acromegaly across the EU and EEA, based on Phase 3 PATHFNDR data showing biochemical and symptom control with a generally well-tolerated safety profile.
This approval, coupled with PALSONIFY’s Orphan Drug Designation in the EU and initial commercialization plans in Germany and Austria, expands Crinetics’ addressable acromegaly...